

Special Issue

Bacterial and Viral Immunity and Vaccination

Message from the Guest Editor

Bacterial and viral infectious diseases pose an ongoing threat to human health, with significant impacts on the public health sector and economic development of affected populations. Compared to other global regions, low- and middle-income countries (LMIC), including those within Sub-Saharan Africa, generally bear a larger burden of these infectious (and often preventable) diseases. It is important that control of and vaccination against infectious diseases within this region continues. This Special Issue aims to present research articles related to the immunology of bacterial and viral pathogens, vaccine immunogenicity, efficacy and effectiveness and factors influencing vaccine performance. Contributions relating to studies or vaccine trials performed in LMIC are also welcome. We are also research (or review) articles that discuss: (i) laboratory-based immunology and/or vaccine studies (ii) on bacterial and/or viral pathogens (iii) using qualitative and/or quantitative approaches in (iv) either pediatric and/or adult populations from different global regions, including LMIC.

Guest Editor

Dr. Martin R. Goodier

MRC Unit The Gambia, London School of Hygiene and Tropical Medicine, London, UK

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159636

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).